Trial Profile
Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 01 Feb 2021 Results published in the Acta Neurologica Scandinavica.
- 02 Jan 2021 Primary endpoint (Disability measured by Expanded Disability Status Scale) has not been met.
- 23 Apr 2019 Status changed from not yet recruiting to completed.